- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Nektar Therapeutics (NKTR)
Nektar Therapeutics stock price live, this page displays NASDAQ NKTR stock exchange data. View the NKTR premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Nektar Therapeutics real time stock price chart below.
What Is the Nektar Therapeutics Stock Price Today?
The Nektar Therapeutics stock price today is 83.2200.
What Is the Stock Symbol for Nektar Therapeutics?
The stock ticker symbol for Nektar Therapeutics is NKTR.
Is NKTR the Same as $NKTR?
$NKTR is a common way to refer to the Nektar Therapeutics ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Nektar Therapeutics Trade On?
Nektar Therapeutics is listed and trades on the NASDAQ stock exchange.
Is Nektar Therapeutics a Good Stock to Buy?
Determining whether Nektar Therapeutics—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Nektar Therapeutics share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NKTR quote. (ISIN: US6402683063)
What Is the Nektar Therapeutics Stock Price Today?
The Nektar Therapeutics stock price today is 83.2200.
What Is the Stock Symbol for Nektar Therapeutics?
The stock ticker symbol for Nektar Therapeutics is NKTR.
Is NKTR the Same as $NKTR?
$NKTR is a common way to refer to the Nektar Therapeutics ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Nektar Therapeutics Trade On?
Nektar Therapeutics is listed and trades on the NASDAQ stock exchange.
Is Nektar Therapeutics a Good Stock to Buy?
Determining whether Nektar Therapeutics—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Nektar Therapeutics share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NKTR quote. (ISIN: US6402683063)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
81.3950
83.7600
52 wk Range
7.9900
83.7600
Trading near 52-week High
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
81.395083.7600
52 wk Range
7.990083.7600
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
NKTR Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
128.1250
Upside
+53.96%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales decline in the current year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Nektar Therapeutics Earnings Call Summary for Q4/2025
- Nektar ended Q4 2025 with $245.8M cash, raising $476M through capital activities to reach ~$720M total liquidity; stock fell 1.15% to $72.49.
- Full-year 2025 revenue totaled $55.2M with net loss of $164.1M ($9.73/share); Q4 revenue reached $21.8M with $36.1M loss ($1.78/share).
- R&D expenses projected to surge to $200-250M in 2026 from $117.3M in 2025, driven by REZPEG phase 3 program starting patient randomization June 2026.
- Company forecasts 2026 non-cash royalty revenue of $40-45M with declining G&A expenses, maintaining substantial cash position through year-end.
Last Updated: 03/12/2026, 06:36 PM
Read Full TranscriptCompare NKTR to Peers and Sector
Metrics to compare | NKTR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNKTRPeersSector | |
|---|---|---|---|---|
P/E Ratio | −14.6x | −4.3x | −0.5x | |
PEG Ratio | 1.18 | −0.05 | 0.00 | |
Price / Book | 26.6x | 1.9x | 2.6x | |
Price / LTM Sales | 43.2x | 5.3x | 3.2x | |
Upside (Analyst Target) | 58.0% | 27.7% | 45.7% | |
Fair Value Upside | Unlock | 8.6% | 4.8% | Unlock |
Analyst Ratings
9 Buy
1 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 128.1250
(+53.96% Upside)
Earnings
Latest Release
Mar 12, 2026
EPS / Forecast
-1.78 / -0.19
Revenue / Forecast
21.81M / 9.71M
People Also Watch
FAQ
What Is the Nektar (NKTR) Stock Price Today?
The Nektar stock price today is 83.2200 USD.
What Stock Exchange Does Nektar Trade On?
Nektar is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Nektar?
The stock symbol for Nektar is "NKTR."
What Is the Nektar Market Cap?
As of today, Nektar market cap is 2.3900B USD.
What Is Nektar's Earnings Per Share (TTM)?
The Nektar EPS (TTM) is -9.7254.
From a Technical Analysis Perspective, Is NKTR a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Nektar Stock Split?
Nektar has split 2 times.
How Many Employees Does Nektar Have?
Nektar has 63 employees.
What is the current trading status of Nektar (NKTR)?
As of Apr 16, 2026, Nektar (NKTR) is trading at a price of 83.2200 USD, with a previous close of 81.2600 USD. The stock has fluctuated within a day range of 81.3950 USD to 83.7600 USD, while its 52-week range spans from 7.9900 USD to 83.7600 USD.
What Is Nektar (NKTR) Price Target According to Analysts?
The average 12-month price target for Nektar is 128.1250 USD, with a high estimate of 165 USD and a low estimate of 70 USD. 9 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +53.96% Upside potential.
What Is the NKTR Premarket Price?
NKTR's last pre-market stock price is 81.7600 USD. The pre-market share volume is 1,250.0000, and the stock has decreased by 0.5000, or 0.6200%.
What Is the NKTR After Hours Price?
NKTR's last after hours stock price is 83.0399 USD, the stock has decreased by -0.1801, or -0.2200%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.